tHEORetically Speaking
Menu Close
  • Home
  • Guest Authors
  • About Us
  • HealthEconomics.Com
  • HE Jobs Portal

Steve Pearson

0

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

Posted on July 30, 2015 by Swarali Tadwalkar

Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing.  The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading →

cost-effectiveness, health economic models, health outcome models, modeling, Pharmaceutical Pricing, simulation, Value Access benchmark reports, comparative effectiveness, cost-effectiveness analysis, Dan Ollendorf, Emerging Therapy Assessment and Pricing, Evidence-based medicine, ICER, Institute for Clinical and Economic Review, patti peeples, pharmaceutical industry, Steve Pearson

About the HealthEconomics.Com Blog:

Insights, observations, executive interviews, critical analysis, and new research for health economics, outcomes research, real-world evidence, and market access community. We welcome guest bloggers.

Check your inbox or spam folder to confirm your subscription.

Recent Posts

  • The Emerging Outcomes Demonstration / Cost Management Challenge
  • Hard to Define, Harder to Find Patients: Using AI & Real-World Data to Understand Treatment Resistant Depression
  • Get to Know R-S-S (Regulatory Scientific and Health Solutions)
  • Will 2023 Be the Year AI Disrupts Healthcare?

HealthEconomics.Com Twitter Feed

HealthEconomics.Com | A Scientist.com Company Follow

www_healthecon
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
24 Mar

AMCP 2023 Panel Argues for Patient-Centered Prior Authorization

http://ow.ly/RZ4050NrAhI

#HEOR #Payers #PatientCentered #Healthcare

Reply on Twitter 1639379097456607233 Retweet on Twitter 1639379097456607233 Like on Twitter 1639379097456607233 1 Twitter 1639379097456607233
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
24 Mar

NICE Recommends Novel Gene Therapy for Rare Genetic Brain Disorder

http://ow.ly/1wIc50NrzLB

#HEOR #RareDisease #OrphanDrug #Therapeutics #GeneTherapy

Reply on Twitter 1639364008468951040 Retweet on Twitter 1639364008468951040 Like on Twitter 1639364008468951040 Twitter 1639364008468951040
www_healthecon HealthEconomics.Com | A Scientist.com Company @www_healthecon ·
24 Mar

Patient Advocacy Groups Decry NIH Refusing to Exert March-In Rights for Prostate Cancer Drug Xtandi

http://ow.ly/mWTS50Nry5X

#HEOR #DrugPrices #Patents #Therapeutics #Pharma

Reply on Twitter 1639348911264636929 Retweet on Twitter 1639348911264636929 Like on Twitter 1639348911264636929 Twitter 1639348911264636929
Load More...

Archives

Visit our website, HealthEconomics.Com, top ranked by Google for news, jobs and resources in healthcare value, market access and more. Read our privacy policy here.
© 2023 tHEORetically Speaking. All rights reserved.
Hiero by aThemes